Aims: Alcoholism may be a cardiovascular risk factor. Osteocyte derived molecules such as fibroblast growth factor 23 (FGF-23) and soluble α Klotho have recently been associated with cardiovascular disease, but their role in alcoholics is unknown. We here analyze the behavior of FGF23 and α Klotho in alcoholics. Methods: Ninety-seven alcoholic patients were assessed for liver function, presence of hypertension, diabetes, atrial fibrillation, left ventricular hypertrophy (LVH), vascular calcifications (assessed by chest X-ray) and nutritional status (lean and fat mass measured by densitometry). We measured plasma levels of FGF-23 and serum soluble α Klotho, using ELISA in 97 patients and 20 age-and sex-matched controls. Results: FGF-23 levels were higher in patients than in controls (Z = 3.50; P < 0.001). FGF-23 (Z = 5.03; P < 0.001) and soluble α Klotho (Z = 5.61; P < 0.001) were higher in cirrhotics, and both were related to liver function, independently of serum creatinine FGF-23 levels were higher among alcoholics with diabetes (Z = 2.55; P = 0.011) or hypertension (Z = 2.56; P = 0.01), and increased body fat (ρ = 0.28; P = 0.022 for trunk fat), whereas α Klotho levels were higher in patients with LVH (Z = 2.17; P = 0.03) or atrial fibrillation (Z = 2.34; P = 0.019). Conclusions: FGF-23 was higher in alcoholics than in controls, especially among cirrhotics, and soluble α Klotho levels were also higher among cirrhotics. Both were related to liver function impairment, independently of serum creatinine levels, and also showed significant associations with vascular risk factors, such as hypertension, diabetes or trunk fat amount in the case of FGF-23, or LVH or atrial fibrillation in the case of α Klotho. Short summary: We report increased values of fibroblast growth factor 23 (FGF-23) and soluble α Klotho in cirrhotic alcoholics. Both molecules are associated with liver function impairment, and with some cardiovascular risk factors such as diabetes, hypertension, increased body fat, left ventricular hypertrophy and atrial fibrillation independently of serum creatinine.
INTRODUCTION
Fibroblast growth factor-23 (FGF-23) is involved in bone metabolism (Razzaque, 2009) . Increased serum phosphorus constitutes a major stimulus for FGF-23 secretion by osteocytes and osteoblasts (Anderson, 2013) . Once secreted, FGF-23 exerts a variety of functions. It inhibits 1 α-hydroxylase both in renal cells and in monocytes leading to decreased vitamin D levels and impaired immune response (Bacchetta et al., 2013) . It also inhibits parathyroid hormone (PTH) secretion (Krajisnik et al., 2007) , although the underlying mechanisms are still unclear (Erben, 2016) . In addition, it has a phosphaturic effect (Andrukhova et al., 2012) , suppressing the activity of sodiumphosphorus (NaPi) cotransporters in the proximal tubule. In accordance with these effects on calcium-phosphorus metabolism, the relationship between FGF23 and bone mineral density (BMD) has been extensively studied with disparate results, although in general either no association or only a weak relationship with BMD have been reported (Kanaan et al., 2010; Manghat et al., 2010; Park et al., 2010) .
Binding of FGF-23 to cells requires a receptor complex that includes FGF receptors, especially FGF receptor 1c and the transmembrane protein α Klotho, that serves as a coreceptor (Urakawa et al., 2006) and increases FGFR's affinity for FGF-23 20-fold (Erben, 2016) . Alpha Klotho is a transmembrane protein that is similar to the family of β glycosidases. The main sites for α Klotho expression are proximal and distal renal tubules, choroid plexus in the central nervous system, and parathyroid glands (Erben, 2016) . The extracellular domain of α Klotho is cleaved, and it can be detected in blood, urine and cerebrospinal fluid as the soluble form of α Klotho (Moe, 2012) . The function of soluble α Klotho is controversial and only partially known. It has been described as an inhibitor of insulin signaling but the receptor for soluble α Klotho has not been identified yet.
In chronic kidney disease FGF-23 levels are independently related to mortality (Gutiérrez et al., 2008) . In advanced chronic kidney disease vascular calcification is a prominent feature, so it has been proposed that FGF-23 may be related to the development of vascular calcification (Jimbo and Shimosawa, 2014) , although considerable controversy exists regarding this point (Scialla et al., 2013) , some data even suggesting a protective role: FGF-23 would rise in order to counteract increased deposition of calcium phosphate salts (Nakahara et al., 2016) .
In chronic alcoholics there are several data that prompt us to study the behavior of the FGF-23/α Klotho axis. Vascular calcifications have been described in heavy alcoholics although their clinical meaning is uncertain. Heavy alcoholism also impairs bone homeostasis and alters the hormones involved in its regulation, including vitamin D and PTH, both of which directly influence calcium-phosphorus homeostasis and are also involved in FGF-23/α Klotho metabolism. Ethanol leads to osteocyte apoptosis (Maurel et al., 2011) . Moreover, a recent report suggests that FGF-23 levels rise when liver damage ensues (Prié et al., 2013) . Therefore, it is possible that FGF-23 and/or α-Klotho levels are altered in alcoholics, especially if there is accompanying liver dysfunction, even in the absence of co-existing kidney failure. Based on these facts, the aim of this study is to analyze the behavior of FGF-23 and α-Klotho in alcoholics and its relationship with ethanol intake, body composition, liver function and some markers of cardiovascular risk.
PATIENTS AND METHODS

Patients and controls
We studied 97 alcoholic patients (four women) who were consecutively admitted to the Internal Medicine ward and who were aged 59.32 ± 11.61 years and drank 172 ± 99 g of alcohol per day for 34 ± 13 years. Sixty-five patients were smokers (number of packyears = 34.92 ± 30.93; median = 30; IR = 13.5-45). Forty patients were cirrhotics. Diagnosis of liver cirrhosis was based on ultrasound examination of the liver and spleen, recording the presence or not of liver heterogeneity and/or nodularity, dilated portal vein and presence or not of splenomegaly, and on clinical (ascites, encephalopathy) and laboratory data (prothrombin activity, albumin and bilirubin). The presence of liver steatosis was also recorded. We also included 20 non-drinkers, non-smokers, healthy hospital workers (three women) who served as controls, aged 56.06 ± 11.61 years (t = 1.14; NS). In Table 1 we show some relevant biological data of the patients included, as well as the mean and median values of FGF-23 and α Klotho in controls. The study was reviewed and approved by the Hospital Universitario de Canarias Institutional Review Board .
Assessment of cardiovascular disease burden
Patient history was taken upon admission to the hospital. Data regarding comorbidities such as diabetes mellitus, hypertension, atrial fibrillation and left ventricular hypertrophy (LVH) were obtained for each patient. LVH was assessed using the SokolowLyon index, following recommended methods.
Nutritional status
Nutritional status was clinically assessed using body mass index. Furthermore, we evaluated body composition. To do this we measured the amount of fat mass and lean mass in different body compartments using a HOLOGIC QDR-2000 (Waltham, MA, USA) dual-energy X-ray densitometer. This exploration was performed in 62 patients.
Laboratory testing
Routine laboratory testing was done on all patients. Specifically, prothrombin activity, bilirubin and albumin were recorded in order to assess liver function and to calculate Child-Pugh's score (Pugh's score); mean corpuscular volume (MCV) and gamma glutamyl transferase (GGT) as 'markers' of ethanol consumption; aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT) and total alkaline phosphatase as enzymes related to liver damage; and serum creatinine. We also collected additional samples for measurement of FGF-23 and α Klotho levels. We used plasma samples for measurement of FGF-23 and serum samples for measurement of α Klotho. All samples were stored at −80°C after centrifugation and were later analyzed in batches. An ELISA was used to determine concentrations of all molecules. FGF-23 was measured using a second generation ELISA (Immutopics, Inc. San Clemente, California). The sensitivity of this assay as determined by the 95% confidence limit on 20 duplicate determinations of the 0 RU/ml standard is 1.5 RU/ml. The interassay and intra-assay coefficients of variation are less than 5%. The percentage of recovery for this assay ranged from 91 to 116%. Alpha Klotho levels were determined by ELISA (Immuno-Biological Laboratories, Fujioka, Japan). Interassay and intrassay variation coefficients range from 2.9 to 11.4% and 2.7 to 3.5%, respectively. The percentage of recovery ranged from 84.7 to 97.5%. Sensitivity is 6.15 pg/ml, and cross reactivity with other molecules such as osteopontin, platelet-derived growth factor or vascular endothelial growth factor is <0.1%.
Assessment of vascular calcifications
Chest radiographs were performed on all patients. Aortic arch calcification was assessed according to the protocol described by Li et al. (2002) , in which radiographs were assessed for the presence of aortic arch calcification and these calcifications were further categorized as ≤1 cm or >1 cm in length
Statistics
Mann-Whitney's U test was used to analyze differences in FGF23 and Klotho levels among two groups of patients, and KruskallWallis test, to determine if there were differences among three or more groups. Spearman's rho was used in correlations of variables. We performed stepwise logistic regression and multiple correlation analyses to disclose to which variables FGF-23 or α Klotho were independently related. Statistical analyses were performed using SPSS software (Chicago, IL, USA).
RESULTS
Marked differences were observed regarding FGF-23 (KruskallWallis test (KW) = 36.75) and α Klotho levels (KW = 33.37; P ≪ 0.001 in both cases) when cirrhotics, non-cirrhotics and controls were compared ( Fig. 1a and b) . With both parameters the differences were established between cirrhotics and controls, whereas no differences were observed between non-cirrhotics and controls in the case of α Klotho. A significant, direct relationship was observed between α Klotho and FGF-23 (ρ = 0.41; P < 0.001). No differences were observed regarding sex. There were no associations between FGF-23 and daily ethanol consumption, years of consumption, MCV or GGT levels, but α Klotho levels were directly, significantly related to daily ethanol consumption (ρ = 0.205; P < 0.045), MCV (ρ = 0.208; P = 0.041) and GGT (ρ = 0.211; P = 0.038). However, after performing a multiple regression analysis introducing these three parameters and liver cirrhosis as independent variables, we found that liver cirrhosis displaced VCM, GGT and ethanol consumption from their relationship with α-Klotho, remaining as the sole variable independently related to α-Klotho (beta = 0.45; P < 0.001).
Differences according to liver function
Forty patients had liver cirrhosis. Significant differences were found regarding FGF-23 (Z = 5.03; P < 0.001) and α Klotho (Z = 5.61; P < 0.001) between cirrhotics and non-cirrhotics. FGF-23 showed inverse correlations with albumin (ρ = −0.32; P < 0.001) and prothrombin (ρ = −0.49; P < 0.001), but direct ones with bilirubin (ρ = 0.34; P < 0.001) and Pugh's score (ρ = 0.45; P < 0.001). Alpha Klotho also showed inverse correlations with albumin (ρ = −0.41; P < 0.001) and prothrombin (ρ = −0.55; P < 0.001), but direct ones with bilirubin (ρ = 0.54; P < 0.001) and Pugh's score (ρ = 0.67; P < 0.001).
Twenty-four patients showed liver steatosis. Alpha Klotho values were significantly lower among patients with steatosis (Z = 2.71; P = 0.007). FGF-23 also showed a trend to lower values among patients with steatosis (Z = 1.87; P = 0.061). Liver steatosis was inversely associated with liver cirrhosis (χ 2 = 11.41; P < 0.001). Therefore, we performed multivariate analyses, disclosing that cirrhosis, but not steatosis, was independently related both to FGF-23 (beta = 0.31; P = 0.003) and α Klotho (beta = 0.44; P < 0.001). Significant relationships were observed between FGF-23 and ASAT (ρ = 0.22; P = 0.03) and between α Klotho and ASAT (ρ = 0.30; P = 0.003). We also found associations between FGF-23 and alkaline phosphatase (ρ = 0.32; P < 0.001) and between α Klotho and alkaline phosphatase (ρ = 0.29; P = 0.004). Plasma FGF-23 (but not α Klotho, ρ = 0.07) levels were directly related to creatinine (ρ = 0.38; P < 0.001). Plasma FGF-23 was also directly related to blood urea nitrogen (ρ = 0.40; P < 0.001). No relationships were observed with serum phosphorus or magnesium. However, we did find an inverse association between serum calcium and FGF-23 (ρ = −0.20; P = 0.048).
When a stepwise logistic regression analysis was performed in order to disclose which variables out of age, prothrombin, albumin, creatinine, and bilirubin were independently related to FGF-23 higher or lower than the median, prothrombin was selected in the first step, followed by creatinine in the second step (Tables 2 and 3) . When Pugh's score was introduced instead of prothrombin, albumin and bilirubin, again it was selected in the first place (beta = 1.51; P < 0.001), followed by creatinine (beta = 1.39; P = 0.018). Pugh's score was the only variable selected when the variable phosphorus levels was also introduced.
Considering FGF-23 as a continuous variable, it showed an independent relationship only with serum albumin (beta = −0.28; P = 0.005), displacing age, creatinine, prothrombin and bilirubin when these parameters were stepwise introduced, or with Pugh's score (beta = 0.32; P = 0.001) when this variable, age and creatinine were introduced.
Regarding α Klotho, when a stepwise logistic regression analysis was performed in order to disclose which variables out of age, prothrombin, albumin, creatinine, and bilirubin were independently related to α Klotho higher or lower than the median, prothrombin was selected in the first step, followed by albumin in the second step. When Pugh's score was introduced, again it was the only variable selected (Tables 4 and 5 ). This also happened when the variable phosphorus was also introduced. Considering α Klotho as a continuous variable and performing a multiple regression analysis, α Klotho showed an independent relationship only with prothrombin (beta = 0.54; P < 0.001), age (beta = 0.18; P = 0.028) and serum albumin (beta = 0.17; P = 0.049), displacing creatinine and bilirubin when these parameters were stepwise introduced, or with Pugh's score (beta = 0.69; P < 0.001) when this variable, age and creatinine were introduced.
Differences according to body composition
No relationship was observed between FGF23 levels and lean mass, besides an inverse correlation with left arm lean mass (ρ = −0.34; P = 0.006). In contrast, FGF-23 levels were significantly related to total fat mass (ρ = 0.34; P = 0.006), trunk fat mass (ρ = 0.28; P = 0.022), right leg fat mass (ρ = 0.35; P = 0.005) and left leg fat mass (ρ = 0.24; P = 0.005), and with BMI (ρ = 0.25; P = 0.04), but not with body weight (ρ = 0.18; P > 0.10). Alpha Klotho levels were not related to either lean mass or fat mass variables, body weight or BMI. The relationship between left arm lean mass and FGF-23 was independent of creatinine levels.
Differences according to cardiovascular disease burden
Eighteen patients showed atrial fibrillation. No relationship was found between FGF-23 levels and the presence of atrial fibrillation. However, patients with atrial fibrillation showed significantly higher α Klotho values (Z = 2.34; P = 0.019). Similarly, no relationship was found between FGF-23 levels and left ventricular hypertrophy, but patients with left ventricular hypertrophy showed significantly higher α Klotho values (Z = 2.17; P = 0.03). Forty-two patients (43.3%) had hypertension. These patients showed significantly higher FGF-23 levels (Z = 2.56; P = 0.010), but not different α Klotho values. Similarly, we found that the 16 diabetic patients had higher FGF-23 values (but not different α Klotho values) than non-diabetic patients in this cohort (Z = 2.55; P = 0.011). No significant relationship was observed between FGF23 and glycated hemoglobin, but an inverse one was obtained between α Klotho and glycated hemoglobin (ρ = −0.27; P = 0.019). Smoking was not related to FGF-23 or α Klotho. No relationship was observed between FGF-23 or α Klotho with the presence or absence of vascular calcifications on chest X-ray (Tables 1 and 6 ).
Regarding FGF-23, the variable hypertension was still selected as an independent factor when a logistic regression analysis was performed including creatinine, age, liver function and body composition. In this analysis Pugh's score was selected first, hypertension in the second place, and left arm lean mass in third place. On the contrary, only Pugh's score was selected when a similar logistic regression analysis was performed with α Klotho.
DISCUSSION
The main finding in this study is the relationship observed between FGF-23 and α Klotho and liver function. We have shown that both variables, α Klotho and FGF-23 levels, are higher among alcoholics than in controls, but also that these differences were dependent on the presence of cirrhosis. Indeed, both variables were closely related to liver function impairment assessed using the Child-Pugh score. The relationships observed with FGF-23 are in agreement with the observations of Prié et al. (2013) , who found that FGF-23 was Table 5 . Logistic regression analysis disclosing an independent relationship between alpha Klotho and prothrombin and albumin for the non-selected ones
Variables not in the equation
Score
Degrees of freedom Sig.
Step 1 significantly higher in patients on a liver transplant waiting list. In that study, FGF-23 correlated with MELD score and was associated with mortality, and the authors also showed that in mice subjected to treatment with diethylnitrosamine FGF-23 levels increased, due to increased production of this phosphatonin by the damaged liver. The mechanisms connecting liver function and FGF-23 levels remain elusive, but, as mentioned, Raimann et al. (2013) showed that mRNA for FGF-23 was present in liver tissue. This observation is also in accordance with the work of Nafidi et al. (2009) who reported that partial hepatectomy is associated with changes in FGF-23 levels. Very recently, Wasserman et al. (2016) described two infants with end stage liver disease secondary to biliary atresia, in whom serum FGF-23 were increased due to ectopic overexpression in hepatocytes. Therefore, it seems that the diseased liver is able to produce FGF-23 in excessive amounts. This would explain the results observed in this study, including the striking association of FGF-23 levels with liver function that in multivariate analyses seems to be more important than creatinine in explaining the increased levels of FGF-23 among alcoholics. Additional important information has been provided in the past months by David et al. (2016) . Decreased iron, either by true deficiency or by iron sequestration, promotes increased FGF-23 production by osteocytes. Although, initially, increased cleavage of intact FGF-23 within the osteocyte maintains normal total FGF-23 levels, it is possible to detect increased levels of C-terminal FGF 23 fragments in serum. In situations of chronic inflammation, sustained FGF-23 overproduction overwhelms the capacity of osteocytes to cleave the FGF 23 intact molecule and thus, its levels increase in serum. This has been shown in experimental models of chronic kidney failure (David et al., 2016) . The triggering signal is probably an increase in hypoxia inducible factor (HIF) 1α, that rises in response to decreased iron availability. A similar mechanism may play a role in alcoholics, given the proinflammatory status associated with alcoholism. The presence of liver cirrhosis, with altered endotoxin clearance by the liver, increased inflammation and increased iron sequestration, could also explain the increased FGF-23 levels found in cirrhotics. This possibility, still speculative, deserves confirmation.
As said, there is a soluble form of α Klotho, whose functions are largely unknown (Lim et al., 2015) . In the present study we found that soluble α Klotho levels were also closely related to liver function derangement, something that is logical given the significant relationship between FGF-23 and α Klotho levels. In a detailed study, Lim et al. (2015) described expression of transmembrane α Klotho in many tissues, but not liver. However, Raimann et al. (2013) established that liver may express α Klotho in piglets, and Chen et al. (2013) also found positive staining for α Klotho in hepatoma cells of 52 patients subjected to liver biopsy. Interestingly, these authors also found a relationship between staining positivity and presence of liver cirrhosis. Both results are in agreement with our findings, i.e. with the close relationship between increased α Klotho levels and liver function impairment, and with the fact that α Klotho levels are by far higher among cirrhotics. In contrast with FGF-23, that was also higher already in non-cirrhotic alcoholics, α Klotho levels in controls are similar to those of non-cirrhotic alcoholics. Assuming that only diseased liver is able to express FGF-23 and α Klotho, it seems that subtle liver changes, as those present in non-cirrhotic alcoholics, suffice to increase FGF-23 levels, whereas α Klotho needs a more intense degree of liver function impairment to be expressed.
Both variables were also associated with some features involved in vascular risk. High FGF-23 levels have been repeatedly associated with LVH (Faul et al., 2011; Itoh and Ohta, 2013) . This may be the result of a direct effect of FGF-23 activating calcineurin/nuclear factor of activated T cells signaling in cardiomyocytes (Itoh and Ohta, 2013) . LVH is a well known cardiovascular risk factor associated with increased mortality independently of hypertension, obesity, and high cholesterol levels (Bombelli et al., 2009) . Also, LVH has been reported in alcoholics (Kupari et al., 1991) , not only in association with hypertension. Dilated cardiomyopathy with reduced wall thickness is also frequently observed among alcoholics (Laonigro et al., 2009) . In our study, the prevalence of left ventricular hypertrophy was similar among alcoholics with hypertension (11 out of 42) than among those without hypertension (15 out of 55). In contrast with many studies (for instance, Faul et al., 2011) , but in accordance with some results in patients without kidney failure (Agarwal et al., 2014) no relationship was observed between FGF-23 and LVH, although in our study LVH was assessed by electrocardiographic methods and not by ultrasound. However, hypertension and diabetes were associated with higher FGF-23 values. The association between FGF-23 and hypertension has also been widely documented (Batra et al., 2016) , although not in alcoholics. Regarding diabetes there are also observational studies incriminating FGF-23 in the progression to end stage renal disease (Titan et al., 2011) , all cause mortality (Lee et al., 2013) , or ischemic events (Tuñón et al., 2016) . In this study alcoholic diabetics showed higher FGF-23 levels than non-diabetics, thus being in accordance with the aforementioned studies, although follow-up time was too short to allow an analysis of the impact of FGF-23 on the development of new vascular complications.
Alpha Klotho was higher among patients with LVH or atrial fibrillation. A negative association was reported between α Klotho and LVH (Tanaka et al., 2016) among patients with kidney failure, but only in a subgroup of them, in contrast with the positive correlation found in this study. Lee et al. (2014) did find high α Klotho in diabetics with early stages of nephropathy, but Wu et al. (2014) found an opposite result. We found an inverse correlation between glycated hemoglobin and α Klotho levels, a result more in accordance with that reported by these last authors; and van Ark et al. (2013) failed to find differences in α Klotho between diabetics and nondiabetics with macrovascular disease. As shown, results are considerably controversial. However, it is important to consider that none of these studies, besides ours, was performed in alcoholics.
Serum levels of FGF-23, but not of α Klotho, were related to fat amount at different parts of the body. Mirza et al. (2011) found a direct relationship between FGF-23, body mass index, waist circumference, and waist to hip ratio among senile men. We also found a direct relationship between FGF-23 and trunk fat, total fat, and fat amount at the lower limbs. Some reports have shown a relationship between obesity and FGF-23, and even a pathogenetic role of FGF-23 on obesity, enhancing synthesis and accumulation of fat in adipocytes (Grethen et al., 2012) . The relationship with trunk fat also suggests that FGF-23 is related to cardiovascular risk, although, as disentangled by the multivariate analysis, the association of FGF-23 and variables related to vascular risk are displaced by liver function tests.
CONCLUSIONS
Therefore we conclude that FGF-23 was higher in alcoholics, especially if they had cirrhosis. Higher FGF-23 values were found among those with liver function derangement. Regarding its association with cardiovascular risk factors, FGF-23 was higher among patients with diabetes, hypertension, and with increased trunk fat. These results strongly support a role of FGF-23 as a cardiovascular risk factor among alcoholics, and the strong dependence on liver function. We have also found that α Klotho is higher among alcoholic cirrhotics, also being related to liver function derangement. Contrary to the conception of α Klotho as a protective, anti-aging factor, we have found that α Klotho levels were higher among alcoholic patients with atrial fibrillation or left ventricular hypertrophy, although, by multivariate analysis, only liver function was selected as an independent factor.
